According to a new report from Intel Market Research, the global biologic medications for psoriasis market was valued at USD 14.5 billion in 2025 and is projected to reach USD 28.7 billion by 2034, growing at a CAGR of 7.8% during the forecast period (2026–2034). This growth is fueled by increasing psoriasis prevalence, superior efficacy of biologics over conventional treatments, and significant advancements in biotechnology. 

Download Sample Report: Biologic Medications for Psoriasis Market - View in Detailed Research Report 

What are Biologic Medications for Psoriasis? 

Biologic medications are advanced therapeutic agents derived from living organisms that precisely target and modulate specific components of the immune system involved in psoriasis pathogenesis. These injectable or infusion-based therapies offer revolutionary treatment for moderate-to-severe cases, providing targeted action with significantly fewer systemic side effects than traditional immunosuppressants. 

This comprehensive report delivers a 360-degree view of the global biologic psoriasis treatment landscape from macro-level market dynamics to micro-level competitive intelligence. We analyze market size trends, technological advancements, pipeline developments, reimbursement scenarios, and strategic opportunities across regions and segments. 

The analysis empowers stakeholders to understand competitive positioning, evaluate business potential, and identify growth avenues. Special focus is given to product differentiation strategies of key players, emerging biosimilar competition, and innovation trends reshaping treatment paradigms. 

Get Full Report Here: Biologic Medications for Psoriasis Market - View Detailed Research Report 

Key Market Drivers 

1. Rising Global Burden of Psoriasis and Treatment Gap 
With approximately 125 million psoriasis patients worldwide including 80% chronic plaque psoriasis cases the need for advanced therapies continues to escalate. While biologics represent the gold standard for moderate-to-severe cases, current penetration remains below 30% in developed markets and single digits in emerging economies, indicating substantial unmet needs. Recent epidemiological studies show psoriasis prevalence increasing by 2-3% annually, correlating with lifestyle changes and environmental factors. 

2. Clinical Superiority and Expanding Therapeutic Applications 
Modern biologics achieve PASI 90 scores (90% skin clearance) in over 60% of patients—a dramatic improvement from traditional therapies' 20-30% efficacy. The precision targeting of cytokines like TNF-α, IL-17, and IL-23 has revolutionized outcomes while reducing adverse effects. Exciting developments include: 

• Extended dosing intervals – New formulations requiring fewer injections (e.g., every 8-12 weeks versus weekly) 

• Combination regimens – Emerging protocols combining biologics with phototherapy or small-molecule drugs 

• Pediatric approvals – Recent FDA/EMA clearances for adolescent psoriasis populations 

Market Challenges 

• Cost Barriers and Access Disparities – With annual treatment costs averaging $50,000-$75,000, biologics remain inaccessible for many patients, especially in developing nations with limited reimbursement. 

• Biosimilar Adoption Hurdles – Despite 15-30% cost savings, physician reluctance and payer policies slow biosimilar uptake in key markets. 

• Cold Chain Complexities – Most biologics require strict temperature control throughout distribution, posing logistical challenges. 

Emerging Opportunities 

The market is entering an exciting phase with untapped potential across: 

• Asia-Pacific expansion – Countries like China and India are reforming healthcare policies to improve biologic access 

• Novel delivery mechanisms – Oral and topical biologics in development could transform administration paradigms 

• Personalized medicine – Biomarker-guided treatment selection improving therapeutic outcomes 

Download Sample Report: Biologic Medications for Psoriasis Market - View in Detailed Research Report 

Regional Market Insights 

• North America – Dominates with 45% market share due to favorable reimbursement, high prescribing rates, and concentration of biologic manufacturers 

• Europe – Strong growth with biosimilar adoption and centralized procurement systems improving access 

• Asia-Pacific – Fastest-growing region (10.2% CAGR) as healthcare systems modernize and awareness increases 

• Latin America – Brazil and Mexico lead adoption through innovative financing models 

• Middle East & Africa – Gulf Cooperation Council countries driving growth through investment in specialty care 

Market Segmentation 

By Drug Class 

• TNF-α Inhibitors (adalimumab, etanercept) 

• IL-17 Inhibitors (secukinumab, ixekizumab) 

• IL-23 Inhibitors (guselkumab, risankizumab) 

• IL-12/23 Inhibitors (ustekinumab) 

• Biosimilars 

By Distribution Channel 

• Hospital Pharmacies 

• Retail Pharmacies 

• Specialty Clinics 

• Online Pharmacies 

By Region 

• North America 

• Europe 

• Asia-Pacific 

• Latin America 

• Middle East & Africa 

Get Full Report Here: Biologic Medications for Psoriasis Market - View Detailed Research Report 

Competitive Landscape 

The market features both established pharmaceutical titans and innovative biotech firms: 

• AbbVie (Humira, Skyrizi) 

• Novartis (Cosentyx) 

• Johnson & Johnson (Tremfya, Stelara) 

• Amgen (Enbrel, Otezla) 

• UCB (Bimzelx) 

• Emerging biosimilar manufacturers (Samsung Bioepis, Biocon) 

Report Deliverables 

• Market size projections through 2034 

• Pipeline analysis and clinical trial insights 

• Regulatory landscape across key markets 

• Reimbursement policy evaluation 

• Competitive benchmarking 

• Emerging technology assessment 

Get Full Report Here: Biologic Medications for Psoriasis Market - View Detailed Research Report 

Download Sample Report: Biologic Medications for Psoriasis Market - View in Detailed Research Report 

About Intel Market Research 

Intel Market Research is a leading provider of strategic intelligence, offering actionable insights in biotechnology, pharmaceuticals, and healthcare infrastructure. Our research capabilities include: 

• Real-time competitive benchmarking 

• Global clinical trial pipeline monitoring 

• Country-specific regulatory and pricing analysis 

• Over 500+ healthcare reports annually 

Trusted by Fortune 500 companies, our insights empower decision-makers to drive innovation with confidence. 

Website: https://www.intelmarketresearch.com 
Asia-Pacific: +91 9169164321 
LinkedIn: Follow Us